Check back for more details.

This work contributes to my bachelor’s thesis. I am designing a bispecific antibody having anti-PD-L1 and anti-CD3 domains; anti-PD-L1 domain can inhibit PD-1/PD-L1 pathway and recruit PD-L1+ tumor cells to CD3+ T-cells, which will mount a suitable immune response. The novelty of this work lies in the combination of biomarkers used, increased binding affinity of paratopes with its respective epitopes, and a unique Fc region consisting of a linker between the two epitope binding domains. This linker makes it easier to synthesize our antibody in mammalian systems at cheaper costs.

We acknowledge the Supercomputing Facility (SCFBio) at Indian Institute of Technology , New Delhi, for providing access to the high performance computing servers and AMBER molecular dynamics simulation modules.

Follow updates on ResearchGate: https://www.researchgate.net/project/Design-and-Expression-of-Anti-PD-L1-anti-CD3-Bispecific-T-cell-Engager-Antibody-for-Enhanced-Onco-Immunotherapy

During my internship in summer 2017, I worked on the optimization of the standard PCR protocol for the identification of Plasmodium sp. and PCR-based detection of mixed infection of P. falciparum and P. vivax in patients attending the Malaria Clinic of NIMR. Now, I am involved in the extension of the project, where currently I am designing an oligonucleotide primer pair that can detect all five human malaria-causing Plasmodium sp. in a single step PCR, thereby reducing labor, capital, and time that is invested in conventional diagnostic methods.